These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

791 related articles for article (PubMed ID: 24684824)

  • 1. Anti-obesity effects of KR-66195, a synthetic DPP-IV inhibitor, in diet-induced obese mice and obese-diabetic ob/ob mice.
    Lee EY; Kim YW; Oh H; Choi CS; Ahn JH; Lee BW; Kang ES; Cha BS; Lee HC
    Metabolism; 2014 Jun; 63(6):793-9. PubMed ID: 24684824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel dipeptidyl peptidase-4 inhibitor teneligliptin prevents high-fat diet-induced obesity accompanied with increased energy expenditure in mice.
    Fukuda-Tsuru S; Kakimoto T; Utsumi H; Kiuchi S; Ishii S
    Eur J Pharmacol; 2014 Jan; 723():207-15. PubMed ID: 24309217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. S 23521 decreases food intake and body weight gain in diet-induced obese rats.
    Claret M; Corominola H; Canals I; Nadal B; Chavanieu A; Pfeiffer B; Renard P; Gorostiaga C; Delagrange P; Grassy G; Gomis R
    Obes Res; 2004 Oct; 12(10):1596-603. PubMed ID: 15536223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.
    Moritoh Y; Takeuchi K; Hazama M
    J Pharmacol Exp Ther; 2009 May; 329(2):669-76. PubMed ID: 19208898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KR-62436, 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile, is a novel dipeptidyl peptidase-IV (DPP-IV) inhibitor with anti-hyperglycemic activity.
    Kim KR; Rhee SD; Kim HY; Jung WH; Yang SD; Kim SS; Ahn JH; Cheon HG
    Eur J Pharmacol; 2005 Jul; 518(1):63-70. PubMed ID: 16106524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
    Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
    J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GLP-1-derived nonapeptide GLP-1(28-36)amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice.
    Tomas E; Wood JA; Stanojevic V; Habener JF
    Regul Pept; 2011 Aug; 169(1-3):43-8. PubMed ID: 21549160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemical cholecystokinin receptor activation protects against obesity-diabetes in high fat fed mice and has sustainable beneficial effects in genetic ob/ob mice.
    Irwin N; Montgomery IA; Moffett RC; Flatt PR
    Biochem Pharmacol; 2013 Jan; 85(1):81-91. PubMed ID: 23085436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-diabetic and anti-inflammatory effect of a novel selective 11β-HSD1 inhibitor in the diet-induced obese mice.
    Park SB; Jung WH; Kang NS; Park JS; Bae GH; Kim HY; Rhee SD; Kang SK; Ahn JH; Jeong HG; Kim KY
    Eur J Pharmacol; 2013 Dec; 721(1-3):70-9. PubMed ID: 24135201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.
    Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
    Eur J Pharmacol; 2008 Jul; 588(2-3):325-32. PubMed ID: 18499100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.
    Irwin N; McClean PL; Flatt PR
    J Pept Sci; 2007 Jun; 13(6):400-5. PubMed ID: 17486662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of sleeve gastrectomy on body weight, food intake, glucose tolerance, and metabolic hormone level in two different rat models: Goto-Kakizaki and diet-induced obese rat.
    Trung VN; Yamamoto H; Yamaguchi T; Murata S; Akabori H; Ugi S; Maegawa H; Tani T
    J Surg Res; 2013 Nov; 185(1):159-65. PubMed ID: 23746960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel black soy peptides with antiobesity effects: activation of leptin-like signaling and AMP-activated protein kinase.
    Jang EH; Moon JS; Ko JH; Ahn CW; Lee HH; Shin JK; Park CS; Kang JH
    Int J Obes (Lond); 2008 Jul; 32(7):1161-70. PubMed ID: 18414417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse.
    Bahrami J; Longuet C; Baggio LL; Li K; Drucker DJ
    Gastroenterology; 2010 Sep; 139(3):857-68. PubMed ID: 20546737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of exercise and food restriction on obesity and diabetes in young ob/ob mice.
    Dubuc PU; Cahn PJ; Willis P
    Int J Obes; 1984; 8(3):271-8. PubMed ID: 6378818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amylin improves the effect of leptin on insulin sensitivity in leptin-resistant diet-induced obese mice.
    Kusakabe T; Ebihara K; Sakai T; Miyamoto L; Aotani D; Yamamoto Y; Yamamoto-Kataoka S; Aizawa-Abe M; Fujikura J; Hosoda K; Nakao K
    Am J Physiol Endocrinol Metab; 2012 Apr; 302(8):E924-31. PubMed ID: 22275759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of genetically obese mice with the iminosugar N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin reduces body weight by decreasing food intake and increasing fat oxidation.
    Langeveld M; van den Berg SA; Bijl N; Bijland S; van Roomen CP; Houben-Weerts JH; Ottenhoff R; Houten SM; van Dijk KW; Romijn JA; Groen AK; Aerts JM; Voshol PJ
    Metabolism; 2012 Jan; 61(1):99-107. PubMed ID: 21816446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour.
    Smith GC; Vickers MH; Cognard E; Shepherd PR
    Schizophr Res; 2009 Nov; 115(1):30-40. PubMed ID: 19679451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, suppresses high fat diet-induced obesity and glucose intolerance in Sprague-Dawley rats.
    Hata T; Mera Y; Tadaki H; Kuroki Y; Kawai T; Ohta T; Kakutani M
    Diabetes Obes Metab; 2011 May; 13(5):446-54. PubMed ID: 21255216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
    Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
    Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.